Identifying and quantifying proteins from mass-spectrometry data
Mass spectrometry generates vast amounts of proteomics data that are difficult to interpret. In data-independent acquisition experiments, overlapping signals require computational analysis to identify proteins and measure their abundance reliably.
Aptila Biotech develops DIA-NN to identify and quantify proteins from mass-spectrometry data. Its software combines automated processing, statistical testing and interactive visualisation for pharmaceutical, biotech and academic research.
What stands out about Aptila Biotech
Thermo Fisher Scientific is a worldwide reseller for DIA-NN Enterprise, extending the software's route to research customers.
DIA-NN Enterprise 2.6.1 reported 9,800–10,112 protein identifications across 1,380 injections in an IonOpticks benchmark.
Indivumed has included DIA-NN in its target-discovery process for deep proteomics analysis in oncology research.
Charité/BIH lists Aptila Biotech among its spin-offs.
Ascenion facilitated Aptila's licence agreement with Charité and holds equity in the company; exclusivity is not claimed.
Founder Vadim Demichev authored DIA-NN and led the MSTARS group at Charité developing mass-spectrometry methods.
Aptila and IonOpticks collaborate on DIA-NN optimisation using chromatography data and support its deployment for method development.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.